Abstract:Abstract Background Cystic Fibrosis (CF) is the most common, lethal autosomal-recessive disorder, and is caused by mutations in the cystic fibrosis transmembrane conductance regulator protein (CFTR), an anion channel that is found in epithelial cells lining multiple organs. The most common mutation of CFTR is deletion of phenylalanine at position 508 (CFTR-F508del), which produces a misfolded protein. This misfolded protein is confined in the endoplasmic reticulum (ER), ubiquitinated and signaled for degradation via the cytosolic proteasome. Previous studies demonstrating experimental restoration of CFTR-F508del (F508del) trafficking to the plasma membrane showed partial function of the chloride channel, raising therapeutic speculations. However, many mechanisms that underly its degradation is still unclear. Results We discovered that the E2 conjugating enzyme, UBE 2L6, aids in the degradation of F508del. We also show that UBE 2L6’s interacting E3 ligase, RNF19B, also assists in F508del degradation. We used siRNA-mediated silencing of endogenous UBE 2L6 and RNF19B in the CF human bronchial epithelial (HBE) cell line CFBE-F508del to demonstrate that there is an increase in F508del-CFTR expression. We also co-expressed UBE 2L6 and RNF 19B with F508del in HEK293 cells that demonstrated a decrease in F508del compared to control. Cycloheximide-chase (CHX) experiments using HEK 293 cells overexpressing RNF19B and F508del showed that there was a decrease in F508del half-life. Lastly, using siRNA-mediated silencing of endogenous UBE 2L6 and RNF19B in CFBE-F508del cells increased forskolin-stimulated short-circuit currents. Interestingly, there seemed to be cooperatively larger increases in short-circuit currents in CFBE-F508del cells that were silenced with UBE 2L6 or RNF19B were treated for 24 hours with VX-809. Conclusion These data suggest that there is an additional mechanism where the E2 conjugating enzyme, UBE 2L6, and the E3 ubiquitin ligase, RNF19B, is responsible for the ubiquitination and subsequent proteasomal degradation of the misfolded F508del. This study presents a novel therapeutic strategy to synergistically restore the function of F508del.

Targeting ubiquitination machinery in cystic fibrosis: Where do we stand?

Ion Channel Modulators in Cystic Fibrosis

Targeting F508del-CFTR to Develop Rational New Therapies for Cystic Fibrosis

Proteostasis Regulators in Cystic Fibrosis: Current Development and Future Perspectives

A Lesson from a Study with the F508del-CFTR Mutant

Cystic Fibrosis Modulator Therapies: Bridging Insights from CF to other Membrane Protein Misfolding Diseases

F508del-CFTR rescue: a matter of cell stress response

A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR

New drugs, new challenges in cystic fibrosis care

Functional Consequences of CFTR Interactions in Cystic Fibrosis

Degradation of CFTR-F508del By the Ubiquitin E2 Conjugating Enzyme UBE 2L6 and the E3 Ligase RNF19B

Pharmacological Rescue of the Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Detected by Use of a Novel Fluorescence Platform

KDM2A and KDM3B as Potential Targets for the Rescue of F508del-CFTR

Evaluation of Autophagy Inducers in Epithelial Cells Carrying the ΔF508 Mutation of the Cystic Fibrosis Transmembrane Conductance Regulator CFTR.

Targeting Proteases in Cystic Fibrosis Lung Disease: Paradigms, Progress, and Potential.

Precision medicine advances in cystic fibrosis: Exploring genetic pathways for targeted therapies

Advances in the Cystic Fibrosis Drug Development Pipeline

Current landscape of cystic fibrosis gene therapy

Gene therapy for cystic fibrosis: Challenges and prospects

[Therapeutics in cystic fibrosis: Clinical revolution and new challenges]

Structure-guided combination therapy to potently improve the function of mutant CFTRs